Pharmaceuticals company Dr. Reddy's Laboratories announced Q2FY26 results Revenue: Rs 88,051 million, change 9.8% YoY; 3% QoQ. EBITDA: Rs 23,511 million for Q2FY26. EBITDA Margin: 26.7% for Q2FY26. PBT: Rs 18,350 million, change -4% YoY; -4% QoQ. PAT: Rs 14,372 million, change 14% YoY; 1% QoQ. G V Prasad, Co-Chairman & MD, said: "Growth in Q2 was driven by momentum in branded markets and steady contributions from the Nicotine Replacement Therapy (NRT) portfolio, which helped offset the decline in U.S. Lenalidomide sales. We remain focused on strengthening our core business, advancing key pipeline assets, driving productivity and Pursuing business development initiatives." Result PDF